Biotech firm Vyome Therapeutics to go public via reverse merger with Nasdaq-listed Reshape Lifesciences

Delhi-based biotech firm Vyome Therapeutics is set to go public in the US through a three-part transaction, including a reverse merger with California-based Reshape Lifesciences, according to statements issued by the companies.

Vyome Therapeutics, a clinical-stage company targeting immuno-inflammatory and rare diseases, backed by Manipal group chief Ranjan Pai and deeptech venture fund Navam Capital, and Nasdaq-listed Reshape Lifesciences, a weight loss solutions company, will merge in an all-stock transaction.